NouvNeu001 Cell Therapy for Parkinson's Disease

Overview

NouvNeu001 is a cell replacement therapy for Parkinson's disease (PD) that uses human dopaminergic progenitor cells derived from stem cells. The therapy aims to restore dopamine production in the brains of patients with mid- to late-stage Parkinson's disease by transplanting dopaminergic neurons that can integrate into the existing neural circuitry and produce dopamine.

Trial Details

Overview

NouvNeu001 is a cell replacement therapy for Parkinson's disease (PD) that uses human dopaminergic progenitor cells derived from stem cells. The therapy aims to restore dopamine production in the brains of patients with mid- to late-stage Parkinson's disease by transplanting dopaminergic neurons that can integrate into the existing neural circuitry and produce dopamine.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06167681 |
| Status | Recruiting |
| Phase | Phase I/II |
| Sponsor | iRegene Therapeutics Co., Ltd. |
| Intervention | NouvNeu001 (human dopaminergic progenitor cells) |
| Route | Intracerebral injection |
| Enrollment | 40 participants (estimated) |
| Start Date | January 17, 2024 |
| Completion Date | July 2029 |
| Locations | Beijing, China; Wuhan, China |

Mechanism of Action

NouvNeu001 represents a cell replacement therapy approach that addresses the core pathological feature of Parkinson's disease — the progressive loss of dopaminergic neurons in the substantia nigra pars compacta.

Cell Therapy Mechanism

• Extend axons to target regions
• Form functional synaptic connections
• Integrate into existing neural circuits

Rationale for Cell Replacement

The loss of dopaminergic neurons in Parkinson's disease leads to:

• Reduced dopamine signaling in the striatum
• Motor symptoms (tremor, bradykinesia, rigidity)
• Eventually, non-motor symptoms (cognitive decline, autonomic dysfunction)

• Replace lost neurons
• Potentially restore normal dopamine regulation
• Slow or halt disease progression
• Improve long-term outcomes

Comparison with Other Cell Therapy Approaches

Embryonic Stem Cell (ESC)-Derived Dopaminergic Neurons

• Source: Derived from human embryonic stem cells
• Advantages: Unlimited proliferative capacity, can be directed to become dopaminergic neurons
• Challenges: Risk of tumor formation (teratomas), ethical concerns, immune rejection
• Examples: Previous trials using fetal tissue (historical), ESC-derived approaches

Induced Pluripotent Stem Cell (iPSC)-Derived Dopaminergic Neurons

• Source: Patient's own cells reprogrammed to pluripotent state, then differentiated
• Advantages: Autologous (patient's own cells), reduced immune rejection, personalized therapy
• Challenges: Expensive, time-consuming (6-12 months to produce cells), variable quality
• Current Status: Several clinical trials in Japan and other countries

NouvNeu001 Approach

| Feature | ESC | iPSC | NouvNeu001 |
|---------|-----|------|------------|
| Source | Embryonic stem cells | Patient's own cells | Allogeneic (donor-derived) |
| Immune Rejection | Requires immunosuppression | Minimal (autologous) | Requires immunosuppression |
| Production Time | Weeks | Months | Off-the-shelf possible |
| Cost | Moderate | High | Potentially lower at scale |
| Tumor Risk | Yes | Lower | Being evaluated |

Advantages of NouvNeu001

Preclinical Evidence

Cell replacement therapy for PD has a long history, with preclinical and clinical evidence supporting the approach:

Animal Models

• Non-human primate studies: Demonstrated that transplanted dopaminergic neurons can survive, integrate, and improve motor function in parkinsonian primates
• Rodent studies: Showed proof of concept for dopamine production and functional recovery

Historical Clinical Evidence

• Fetal tissue transplants (1980s-1990s): Showed some patients experienced significant improvement, but results were variable and the approach was discontinued due to ethical concerns and inconsistent outcomes
• Modern cell therapy: Newer approaches using ESC and iPSC derivatives have shown promise in early-phase clinical trials

Study Design

Phase I/II Trial (NCT06167681)

Primary Objectives:

• Assess safety and tolerability of NouvNeu001 injection
• Evaluate efficacy through motor function assessments

• Adverse events (safety monitoring)
• Motor function improvement (UPDRS scores)
• Quality of life measures

• Diagnosis of idiopathic Parkinson's disease
• Mid- to late-stage disease
• On/off fluctuations or inadequate response to standard therapy

Safety Considerations

Potential Risks

Risk Mitigation

• Careful surgical technique
• Immunosuppressive therapy as needed
• Rigorous cell characterization and quality control
• Close monitoring during follow-up

Significance for Parkinson's Disease

NouvNeu001 represents an important step in the development of disease-modifying therapies for Parkinson's disease:

Comparison with Other PD Therapies

| Therapy Type | Approach | Disease-Modifying Potential |
|--------------|----------|----------------------------|
| Levodopa/Dopamine Agonists | Symptomatic relief | None |
| Deep Brain Stimulation | Electrical modulation | None |
| GDNF/Neurturin | Protein delivery | Potential |
| Alpha-Synuclein Therapies | Target aggregation | Potential |
| Cell Replacement (NouvNeu001) | Replace neurons | High potential |

• [Parkinson's Disease](/genes/ar)
• [Dopamine](/proteins/d1-dopamine-receptor)
• [Alpha-Synuclein](/mechanisms/alpha-synuclein)
• [LRRK2](/proteins/lrrk2)
• [Cell Therapy](/therapeutics/cell-therapy)
• Regenerative Medicine
• [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
• [Clinical Trials in Parkinson's Disease](/genes/ar)

External Links

• [ClinicalTrials.gov - NCT06167681](https://clinicaltrials.gov/study/NCT06167681)
• [iRegene Therapeutics](https://www.iregene.com/)
• [Parkinson's Foundation - Cell Therapy](https://www.parkinson.org/)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving NouvNeu001 Cell Therapy for Parkinson's Disease discovered through SciDEX knowledge graph analysis: